Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer’s Disease

Neurotherapeutics

Volumn 12, Issue 1, 2015, Pages 132-142

  Kim, Tae Wan ^a  

^a Department of Medicine   (United States)

Author keywords

Alzheimer s disease; drug discovery; Drug repositioning; drug repurposing; phenotypic screening; therapeutics; treatment

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; APOLIPOPROTEIN E4; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHOLINESTERASE INHIBITOR; CITALOPRAM; DESVENLAFAXINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ETIRACETAM; FLUOXETINE; IMIDAPRIL; IMIPRAMINE; ISRADIPINE; LIXISENATIDE; LOSARTAN; METFORMIN; NEW DRUG; OLMESARTAN; PAROXETINE; PRESENILIN 1; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TAU PROTEIN; VALPROIC ACID; VALSARTAN;

ALZHEIMER DISEASE; BIOLOGICAL ACTIVITY; BIPOLAR DISORDER; COGNITION; COGNITIVE DEFECT; DRUG INDUSTRY; DRUG REPOSITIONING; DRUG SAFETY; GENE EXPRESSION; GENETIC ASSOCIATION; GLIA CELL; HUMAN; HYPERTENSION; IN VIVO STUDY; MEMORY DISORDER; NONHUMAN; PATENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN SECRETION; PUBLIC-PRIVATE PARTNERSHIP; PYRAMIDAL NERVE CELL; REVIEW; STEM CELL; ANIMAL;

ALZHEIMER DISEASE; ANIMALS; DRUG REPOSITIONING; HUMANS;

EID: 84926649589     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-014-0325-7     Document Type: Review

References (144)

1. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 2011;10:428-438.
2. Schulze U, Baedeker M, Chen YT, Greber D. R&D productivity: on the comeback trail. Nat Rev Drug Discov 2014;13:331-332.
3. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012;11:191-200.
4. Citron M. Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov 2010;9:387-398.
5. Lo AW, Ho C, Cummings J, Kosik KS. Parallel discovery of Alzheimer’s therapeutics. Sci Transl Med 2014;6:241cm5.
6. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014;6:37.
7. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol 2014;32:40-51.
8. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673-683.
9. Jin G, Wong ST. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 2014;19:637-644.
10. Mullard A. Drug repurposing programmes get lift off. Nat Rev Drug Discov. 2012;11:505-506.
11. Cummings JL, Zhong K. Repackaging FDA-approved drugs for degenerative diseases: promises and challenges. Expert Rev Clin Pharmacol 2014;7:161-165.
12. Appleby BS, Cummings JL. Discovering new treatments for Alzheimer’s disease by repurposing approved medications. Curr Top Med Chem 2013;13:2306-2327.
13. Corbett A, Pickett J, Burns A, et al. Drug repositioning for Alzheimer’s disease. Nat Rev Drug Discov 2012;11:833-846.
14. Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ Jr. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol 2006;2:415-416.
15. Zhang M, Luo G, Zhou Y, Wang S, Zhong Z. Phenotypic screens targeting neurodegenerative diseases. J Biomol Screen 2014;19:1-16.
16. Huang R, Southall N, Wang Y, et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 2011;3:80ps16.
17. Awouters FH, Lewi PJ. Forty years of antipsychotic Drug research—from haloperidol to paliperidone—with Dr. Paul Janssen. Arzneimittelforschung 2007;57:625-632.
18. Aronson JK. Old drugs—New uses. Br J Clin Pharmacol 2007;64:563-565.
19. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011;10:507-519.
20. Pruss RM. Phenotypic screening strategies for neurodegenerative diseases: a pathway to discover novel drug candidates and potential disease targets or mechanisms. CNS Neurol Disord Drug Targets 2010;9:693-700.
21. Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J Med Chem 2012;55:4527-4538.
22. Chakrabarti E, Smith JD. Drug library screen to identify compounds that decrease secreted Abeta from a human cell line. Curr Alzheimer Res 2005;2:255-259.
23. Utsuki T, Yu QS, Davidson D, et al. Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer’s disease amyloid-beta peptide. J Pharmacol Exp Ther 2006;318:855-862.
24. Spilman P, Descamps O, Gorostiza O, et al. The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer’s model. Brain Res 2014;1551:25-44.
25. Seyb KI, Schuman ER, Ni J, Huang MM, Michaelis ML, Glicksman MA. Identification of small molecule inhibitors of beta-amyloid cytotoxicity through a cell-based high-throughput screening platform. J Biomol Screen 2008;13:870-878.
26. Dickey CA, Eriksen J, Kamal A, et al. Development of a high throughput drug screening assay for the detection of changes in tau levels—proof of concept with HSP90 inhibitors. Curr Alzheimer Res 2005;2:231-238.
27. Dehdashti SJ, Zheng W, Gever JR, et al. A high-throughput screening assay for determining cellular levels of total tau protein. Curr Alzheimer Res 2013;10:679-687.
28. Chen HK, Liu Z, Meyer-Franke A, et al. Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. J Biol Chem 2012;287:5253-5266.
29. Honarnejad K, Kirsch AK, Daschner A, Szybinska A, Kuznicki J, Herms J. FRET-based calcium imaging: a tool for high-throughput/content phenotypic drug screening in Alzheimer disease. J Biomol Screen 2013;18:1309-1320.
30. Longo FM, Yang T, Xie Y, Massa SM. Small molecule approaches for promoting neurogenesis. Curr Alzheimer Res 2006;3:5-10.
31. Lee JA, Chu S, Willard FS, et al. Open innovation for phenotypic drug discovery: The PD2 assay panel. J Biomol Screen 2011;16:588-602.
32. Liang Y, Lin S, Beyer TP, et al. A Liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem 2004;88:623-634.
33. McIntire LB, Landman N, Kang MS, et al. Phenotypic assays for β-amyloid in mouse embryonic stem cell-derived neurons. Chem Biol 2013;20:956-967.
34. Blanchard BJ, Chen A, Rozeboom LM, Stafford KA, Weigele P, Ingram VM. Efficient reversal of Alzheimer’s disease fibril formation and elimination of neurotoxicity by a small molecule. Proc Natl Acad Sci U S A 2004;101:14326-14332.
35. McKoy AF, Chen J, Schupbach T, Hecht MH. A novel inhibitor of amyloid β (Aβ) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease. J Biol Chem 2012;287:38992-39000.
36. Walker LC, Diamond MI, Duff KE, Hyman BT. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol 2013;70:304-310.
37. Holmes BB, Diamond MI. Prion-like properties of tau protein: the importance of extracellular tau as a therapeutic target. J Biol Chem 2014;289:19855-19861.
38. Sharma P, Ando DM, Daub A, Kaye JA, Finkbeiner S. High-throughput screening in primary neurons. Methods Enzymol 2012;506:331-360.
39. Xu X, Lei Y, Luo J, et al. Prevention of β-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of Cyclin-dependent kinases and associated cell cycle events. Stem Cell Res 2013;10:213-227.
40. Cundiff PE, Anderson SA. Impact of induced pluripotent stem cells on the study of central nervous system disease. Curr Opin Genet Dev 2011;21:354-361.
41. Marchetto MC, Gage FH. Modeling brain disease in a dish: really? Cell Stem Cell 2012;10:642-645.
42. Blanpain C, Daley GQ, Hochedlinger K, Passegué E, Rossant J, Yamanaka S. Stem cells assessed. Nat Rev Mol Cell Biol 2012;13:471-476.
43. Grskovic M, Javaherian A, Strulovici B, Daley GQ. Induced pluripotent stem cells—opportunities for disease modelling and drug discovery. Nat Rev Drug Discov 2011;10:915-929.
44. Ebert AD, Svendsen CN. Human stem cells and drug screening: opportunities and challenges. Nat Rev Drug Discov 2010;9:367-372.
45. Han SS, Williams LA, Eggan KC. Constructing and deconstructing stem cell models of neurological disease. Neuron 2011;70:626-644.
46. Yagi T, Ito D, Okada Y, et al. Modeling familial Alzheimer’s disease with induced pluripotent stem cells. Hum Mol Genet 2011;20:4530-4539.
47. Yahata N, Asai M, Kitaoka S, et al. Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer’s disease. PLoS One 2011;6:e25788.
48. Israel MA, Yuan SH, Bardy C, et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature 2012;482:216-220.
49. Shi Y, Kirwan P, Smith J, MacLean G, Orkin SH, Livesey FJ. A human stem cell model of early Alzheimer’s disease pathology in Down syndrome. Sci Transl Med 2012;4:124ra29.
50. Koch P, Tamboli IY, Mertens J, et al. Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of γ-secretase activity in endogenous amyloid-β generation. Am J Pathol 2012;180:2404-2416.
51. Kondo T, Asai M, Tsukita K, et al. Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell 2013;12:487-496.
52. Vazin T, Ball KA, Lu H, et al. Efficient derivation of cortical glutamatergic neurons from human pluripotent stem cells: a model system to study neurotoxicity in Alzheimer’s disease. Neurobiol Dis 2014;62:62-72.
53. Zhang D, Pekkanen-Mattila M, Shahsavani M, Falk A, Teixeira AI, Herland A. A 3D Alzheimer’s disease culture model and the induction of P21-activated kinase mediated sensing in iPSC derived neurons. Biomaterials 2014;35:1420-1428.
54. Choi SH, Kim YH, Hebisch M, et al. A three-dimensional human neural cell culture model of Alzheimer’s disease. Nature 2014;515:274-278.
55. Young JE, Goldstein LS. Alzheimer’s disease in a dish: promises and challenges of human stem cell models. Hum Mol Genet 2012;21:R82-R89.
56. Guo Q, Wang Z, Li H, Wiese M, Zheng H. APP physiological and pathophysiological functions: insights from animal models. Cell Res 2012;22:78-89.
57. McColl G, Roberts BR, Pukala TL, et al. Utility of an improved model of amyloid-beta (Aβ1–42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease. Mol Neurodegener 2012;7:57.
58. Matlack KE, Tardiff DF, Narayan P, et al. Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity. Proc Natl Acad Sci U S A 2014;111:4013-4018.
59. Singh N, Halliday AC, Thomas JM, et al. A safe lithium mimetic for bipolar disorder. Nat Commun 2013;4:1332.
60. Dubus E, Ijjaali I, Barberan O, Petitet F. Drug repositioning using in silico compound profiling. Future Med Chem 2009;1:1723-1736.
61. Dudley JT, Sirota M, Shenoy M, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 2011;3:96ra76.
62. Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther 2013;93:335-341.
63. Harrold JM, Ramanathan M, Mager DE. Network-based approaches in drug discovery and early development. Clin Pharmacol Ther 2013;94:651-658.
64. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-1935.
65. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 2007;7:54-60.
66. Sirota M, Dudley JT, Kim J, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011;3:96ra77.
67. Williams G. A searchable cross-platform gene expression database reveals connections between drug treatments and disease. BMC Genomics. 2012;13:12.
68. Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, Cardon LR, Mooser V. Use of genome-wide association studies for drug repositioning. Nat Biotechnol 2012;30:317-320.
69. Cao C, Moult J. GWAS and drug targets. BMC Genomics 2014;15:S5.
70. Stefansson H, Steinberg S, Petursson H, et al. Variant in the sequence of the LINGO1 gene confers risk of essential tremor. Nat Genet 2009;41:277-279.
71. Clark LN, Park N, Kisselev S, Rios E, Lee JH, Louis ED. Replication of the LINGO1 gene association with essential tremor in a North American population. Eur J Hum Genet 2010;18:838-843.
72. Heinrich M, Lee Teoh H. Galanthamine from snowdrop—the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge. J Ethnopharmacol 2004;92:147-162.
73. Wang J, Zhao Z, Lin E, et al. Unintended effects of cardiovascular drugs on the pathogenesis of Alzheimer’s disease. PLoS One 2013;8:e65232
74. Chow TW, Pollock BG, Milgram NW. Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer’s disease. Neuropsychiatr Dis Treat 2007;3:627-636.
75. Cummings JL, Zhong K. Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nat Rev Drug Discov 2006;5:64-74.
76. Nitsch RM, Deng M, Growdon JH, Wurtman RJ. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem 1996;271:4188-4194.
77. Arjona AA, Pooler AM, Lee RK, Wurtman RJ. Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. Brain Res 2002;951:135-140.
78. Shen F, Smith JA, Chang R, et al. 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: a pharmacodynamic and pharmacokinetic assessment. Neuropharmacology 2011;61:69-79.
79. Pákáski M, Bjelik A, Hugyecz M, Kása P, Janka Z, Kálmán J. Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. Neurochem Int 2005;47:190-195.
80. Nelson RL, Guo Z, Halagappa VM, et al. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol 2007;205:166-176.
81. Cirrito JR, Disabato BM, Restivo JL, et al. Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A 2011;108:14968-14973.
82. Sheline YI, West T, Yarasheski K, et al. An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med 2014;6:236re4.
83. Verret L, Mann EO, Hang GB, et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 2012;149:708-721.
84. Vossel KA, Beagle AJ, Rabinovici GD, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol 2013;70:1158-1166.
85. Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci U S A 2012;109:E2895-E2903.
86. Shi JQ, Wang BR, Tian YY, et al. Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice. CNS Neurosci Ther 2013;19:871-881.
87. Mark RJ, Ashford JW, Goodman Y, Mattson MP. Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol Aging 1995;16:187-198.
88. Qing H, He G, Ly PT, et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer’s disease mouse models. J Exp Med 2008;205:2781-2789.
89. Smith AM, Gibbons HM, Dragunow M. Valproic acid enhances microglial phagocytosis of amyloid-beta(1-42). Neuroscience 2010;169:505-515.
90. Wang Z, Zhang XJ, Li T, Li J, Tang Y, Le W. Valproic acid reduces neuritic plaque formation and improves learning deficits in APP(Swe) /PS1(A246E) transgenic mice via preventing the prenatal hypoxia-induced down-regulation of neprilysin. CNS Neurosci Ther 2014;20:209-217.
91. Long Z, Zheng M, Zhao L, et al. Valproic acid attenuates neuronal loss in the brain of APP/PS1 double transgenic Alzheimer’s disease mice model. Curr Alzheimer Res 2013;10:261-269.
92. Tariot PN, Schneider LS, Cummings J, et al.; Alzheimer’s Disease Cooperative Study Group. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011;68:853-861.
93. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-1145.
94. Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2002;58:1175-1181.
95. Gottesman RF, Schneider AL, Albert M, et al. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurol 2014;71:1218–1227.
96. Yamada K, Uchida S, Takahashi S, et al. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer’s disease. Brain Res 2010;1352:176-186.
97. Dong YF, Kataoka K, Tokutomi Y, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease. FASEB J 2011;25:2911-2920.
98. Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch. Neurol 2006;63:686-692.
99. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069-1075.
100. Paris D, Bachmeier C, Patel N, et al. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Mol Med 2011;17:149-162.
101. Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D. Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood–brain barrier. Eur J Pharmacol 2011;659:124-129.
102. Paris D, Quadros A, Humphrey J, et al. Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res 2004;999:53-61.
103. Hanyu H, Hirao K, Shimizu S, Sato T, Kiuchi A, Iwamoto T. Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int J Geriatr Psychiatry 2007;22:1264-1266.
104. Matsuda H, Araki N, Kuji I, Ohkubo T, Imabayashi E, Shimazu K. Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease. Clin Nucl Med 2008;33:34-35.
105. Hanyu H, Hirao K, Shimizu S, Iwamoto T, Koizumi K, Abe K. Favourable effects of nilvadipine on cognitive function and regional cerebral blood flow on SPECT in hypertensive patients with mild cognitive impairment. Nucl Med Commun 2007;28:281-287.
106. Kennelly S, Abdullah L, Kenny RA, et al. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer’s patients–an open-label trial. Int J Geriatr Psychiatry 2012;27:415-422.
107. Anekonda TS, Quinn JF, Harris C, Frahler K, Wadsworth TL, Woltjer RL. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer’s disease. Neurobiol Dis 2011;41:62-70.
108. Anekonda TS, Quinn JF. Calcium channel blocking as a therapeutic strategy for Alzheimer’s disease: the case for isradipine. Biochim Biophys Acta 2011;1812:1584-1590.
109. Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010;340:b5465.
110. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias. J Alzheimers Dis 2011;26:699-708.
111. Wang J, Ho L, Chen L, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007;117:3393-3402.
112. Danielyan L, Klein R, Hanson LR, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res 2010;13:195-201.
113. Lithell H, Hansson L, Skoog I, et al; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886.
114. Anderson C, Teo K, Gao P, et al.; ONTARGET and TRANSCEND Investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 2011;10:43-53.
115. Howlett DR, George AR, Owen DE, Ward RV, Markwell RE. Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation. Biochem J 1999;343:419-423.
116. Wang J, Ono K, Dickstein DL, et al. Carvedilol as a potential novel agent for the treatment of Alzheimer’s disease. Neurobiol Aging 2011;32:2321.e1-12.
117. Yang Y, Song W. Molecular links between Alzheimer’s disease and diabetes mellitus. Neuroscience 2013;250:140-150.
118. Butterfield DA, Di Domenico F, Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim Biophys Acta 2014;1842:1693-1706.
119. Devi L, Alldred MJ, Ginsberg SD, Ohno M. Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer’s disease. PLoS One 2012;7:e32792.
120. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69:29-38.
121. Gengler S, McClean PL, McCurtin R, Gault VA, Hölscher C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 2012;33:265-276.
122. McClean PL, Parthsarathy V, Faivre E, Hölscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci 2011;31:6587-6594.
123. McClean PL, Hölscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology 2014;76:57-67.
124. Hunter K, Hölscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012;13:33.
125. Chen Y, Zhou K, Wang R, et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer’s amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A 2009;106:3907-3912.
126. Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes. Neuropharmacology 2011;60:910-920.
127. Li J, Deng J, Sheng W, Zuo Z. Metformin attenuates Alzheimer’s disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav 2012;101:564-574.
128. Kickstein E, Krauss S, Thornhill P, et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A 2010;107:21830-21835.
129. Vlachopoulos C, Terentes-Printzios D, Ioakeimidis N, Rokkas K, Stefanadis C. PDE5 inhibitors in non-urological conditions. Curr Pharm Des 2009;15:3521-3539.
130. Puzzo D, Staniszewski A, Deng SX, et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer’s disease mouse model. J Neurosci 2009;29:8075-8086.
131. García-Barroso C, Ricobaraza A, Pascual-Lucas M, et al. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology 2013;64:114-123.
132. Cuadrado-Tejedor M, Hervias I, Ricobaraza A, et al. Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer’s disease. Br J Pharmacol 2011;164:2029-2041.
133. Zhang J, Guo J, Zhao X, et al. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav Brain Res 2013;250:230-237.
134. García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R. Phosphodiesterases as therapeutic targets for Alzheimer’s disease. ACS Chem Neurosci 2012;3:832-844.
135. Allison M. NCATS launches drug repurposing program. Nat Biotechnol 2012;30:571-572.
136. Hennequin LF, Ballard P, Boyle FT, et al. Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2006;16:2672-2676.
137. Nygaard HB, van Dyck CH, Strittmatter SM. Fyn kinase inhibition as a novel therapy for Alzheimer’s disease. Alzheimers Res Ther 2014;6:8.
138. Roberson ED, Halabisky B, Yoo JW, et al. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. J Neurosci 2011;31:700-711.
139. Larson M, Sherman MA, Amar F, et al. The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer’s disease. J Neurosci 2012;32:16857-16871a.
140. Um JW, Nygaard HB, Heiss JK, et al. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 2012;15:1227-1235.
141. Shineman DW, Alam J, Anderson M, et al. Overcoming obstacles to repurposing for neurodegenerative disease. Ann Clin Transl Neurol 2014;1:512-518.
142. Rai AK, Rice G. Use patents can be useful: the case of rescued drugs. Sci Transl Med 2014;6:248fs30.
143. Burness CB, Deeks ED. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS Drugs 2014;28:373-387.
144. Sem DS. Repurposing - finding new uses for old (and patented) drugs: bridging the “valley of death,” to translate academic research into new medicines, 18 Marq. Intellectual Property L Rev 2014;18:139-166.